196 related articles for article (PubMed ID: 37227492)
21. Chimeric antigen receptor T cells march into T cell malignancies.
Tang J; Zhao X
J Cancer Res Clin Oncol; 2023 Nov; 149(14):13459-13475. PubMed ID: 37468610
[TBL] [Abstract][Full Text] [Related]
22. Developing Targeted Therapies for T Cell Acute Lymphoblastic Leukemia/Lymphoma.
DuVall AS; Wesevich A; Larson RA
Curr Hematol Malig Rep; 2023 Dec; 18(6):217-225. PubMed ID: 37490229
[TBL] [Abstract][Full Text] [Related]
23. Biomarkers as targets for CAR-T/NK cell therapy in AML.
Shao R; Li Z; Xin H; Jiang S; Zhu Y; Liu J; Huang R; Xu K; Shi X
Biomark Res; 2023 Jun; 11(1):65. PubMed ID: 37330575
[TBL] [Abstract][Full Text] [Related]
24. Harnessing the Immune System: Current and Emerging Immunotherapy Strategies for Pediatric Acute Lymphoblastic Leukemia.
Glasser CL; Chen J
Biomedicines; 2023 Jul; 11(7):. PubMed ID: 37509525
[TBL] [Abstract][Full Text] [Related]
25. Engineering enhanced chimeric antigen receptor-T cell therapy for solid tumors.
Neeser A; Ramasubramanian R; Wang C; Ma L
Immunooncol Technol; 2023 Sep; 19():100385. PubMed ID: 37483659
[TBL] [Abstract][Full Text] [Related]
26. Recent advances and future perspectives of CAR-T cell therapy in head and neck cancer.
Hu C; Liu M; Li Y; Zhao Y; Sharma A; Liu H; Schmidt-Wolf IGH
Front Immunol; 2023; 14():1213716. PubMed ID: 37457699
[TBL] [Abstract][Full Text] [Related]
27. Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy.
Zheng Z; Li S; Liu M; Chen C; Zhang L; Zhou D
Cancers (Basel); 2023 Jul; 15(13):. PubMed ID: 37444586
[TBL] [Abstract][Full Text] [Related]
28. Acute Lymphoblastic Leukemia Immunotherapy Treatment: Now, Next, and Beyond.
Aureli A; Marziani B; Venditti A; Sconocchia T; Sconocchia G
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444456
[TBL] [Abstract][Full Text] [Related]
29. Inserting EF1α-driven CD7-specific CAR at CD7 locus reduces fratricide and enhances tumor rejection.
Jiang J; Chen J; Liao C; Duan Y; Wang Y; Shang K; Huang Y; Tang Y; Gao X; Gu Y; Sun J
Leukemia; 2023 Aug; 37(8):1660-1670. PubMed ID: 37391486
[TBL] [Abstract][Full Text] [Related]
30. T-cell redirecting therapies for B-cell non-Hodgkin lymphoma: recent progress and future directions.
Russler-Germain DA; Ghobadi A
Front Oncol; 2023; 13():1168622. PubMed ID: 37465110
[TBL] [Abstract][Full Text] [Related]
31. FLT3-directed UniCAR T-cell therapy of acute myeloid leukaemia.
Peschke JC; Bergmann R; Mehnert M; Gonzalez Soto KE; Loureiro LR; Mitwasi N; Kegler A; Altmann H; Wobus M; Máthé D; Szigeti K; Feldmann A; Bornhäuser M; Bachmann M; Fasslrinner F; Arndt C
Br J Haematol; 2023 Sep; 202(6):1137-1150. PubMed ID: 37460273
[TBL] [Abstract][Full Text] [Related]
32. Chimeric antigen receptor T cells for acute myeloid leukemia.
Fetsch V; Zeiser R
Eur J Haematol; 2024 Jan; 112(1):28-35. PubMed ID: 37455578
[TBL] [Abstract][Full Text] [Related]
33. Supportive care for chimeric antigen receptor T-cell patients.
Springell D; O'Reilly M; Roddie C
Curr Opin Support Palliat Care; 2023 Sep; 17(3):231-239. PubMed ID: 37418578
[TBL] [Abstract][Full Text] [Related]
34. CD7 protein plays a crucial role in T cell infiltration in tumors.
Sheng B; Zhang K; Tian S; Ma R; Li Z; Wu H; Wang T; Jiang L; You F; An G; Meng H; Yang L; Liu X
Heliyon; 2023 Jun; 9(6):e16961. PubMed ID: 37416646
[TBL] [Abstract][Full Text] [Related]
35. Site-specific transgene integration in chimeric antigen receptor (CAR) T cell therapies.
Dabiri H; Safarzadeh Kozani P; Habibi Anbouhi M; Mirzaee Godarzee M; Haddadi MH; Basiri M; Ziaei V; Sadeghizadeh M; Hajizadeh Saffar E
Biomark Res; 2023 Jul; 11(1):67. PubMed ID: 37403182
[TBL] [Abstract][Full Text] [Related]
36. Novel strategies to prevent and overcome relapse after allogeneic hematopoietic cell transplantation in acute lymphoblastic leukemia.
Hodroj MH; Abou Dalle I; Moukalled N; El Cheikh J; Mohty M; Bazarbachi A
Front Immunol; 2023; 14():1191912. PubMed ID: 37359547
[TBL] [Abstract][Full Text] [Related]
37. Relapsed Acute Lymphoblastic Leukemia.
Sidhu J; Gogoi MP; Krishnan S; Saha V
Indian J Pediatr; 2024 Feb; 91(2):158-167. PubMed ID: 37341952
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapy in leukaemia.
Mu X; Chen C; Dong L; Kang Z; Sun Z; Chen X; Zheng J; Zhang Y
Acta Biochim Biophys Sin (Shanghai); 2023 Jun; 55(6):974-987. PubMed ID: 37272727
[TBL] [Abstract][Full Text] [Related]
39. Myeloid lineage switch following CD7-targeted chimeric antigen receptor T-cell therapy in relapsed/refractory T-cell acute lymphoblastic leukemia.
Aldoss I; Tizro P; Bedi D; Mangan JK; Clark MC; Spencer D; Song JY; Cherian S; Pillai R; Kim Y; Mahajan N; Gendzekhadze K; James M; Jacobs K; Davidson-Moncada J; Forman SJ; Wang HY; Afkhami M
Haematologica; 2023 Dec; 108(12):3511-3516. PubMed ID: 37470155
[No Abstract] [Full Text] [Related]
40. Donor-derived CD19-targeted chimeric antigen receptor T cells in adult transplant recipients with relapsed/refractory acute lymphoblastic leukemia.
Aldoss I; Khaled SK; Wang Y; Wang X; Palmer J; Clark MC; Wagner JR; Paul J; Vyas V; Brown CE; Forman SJ
Blood Cancer J; 2023 Jul; 13(1):107. PubMed ID: 37438346
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
